The role of B cells and humoral immunity in Mycobacterium tuberculosis infection

Seminars in Immunology

Volumn 26, Issue 6, 2014, Pages 588-600

  Chan, John ^a   Mehta, Simren ^a   Bharrhan, Sushma ^a   Chen, Yong ^a   Achkar, Jacqueline M ^a   Casadevall, Arturo ^a   Flynn, JoAnne ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; B cells; Fc R; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

ANTIBODY; ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 10; BACTERIUM ANTIBODY; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN M;

B LYMPHOCYTE; CELLULAR IMMUNITY; GRANULOMA; GRANULOMATOUS INFLAMMATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS; TUBERCULOUS GRANULOMA; ANIMAL; ANTIGEN PRESENTATION; BIOSYNTHESIS; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LUNG; MICROBIOLOGY; MOUSE; PATHOLOGY;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGEN PRESENTATION; B-LYMPHOCYTES; CYTOKINES; GRANULOMA; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN M; LUNG; MICE; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, IGG; TUBERCULOSIS, PULMONARY;

EID: 84920127628     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.10.005     Document Type: Review

References (241)

1. WHO WHO report 2013: global tuberculosis control 2013.
2. Bates J.H., Stead W.W. The history of tuberculosis as a global epidemic. Med Clin North Am 1993, 77:1205-1217.
3. Gagneux S. Host-pathogen coevolution in human tuberculosis. Philos Trans R Soc Lond B Biol Sci 2012, 367:850-859.
4. Comas I., Coscolla M., Luo T., Borrell S., Holt K.E., Kato-Maeda M., et al. Out-of-Africa migration and neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet 2013, 45:1176-1182.
5. Flynn J.L., Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol 2003, 15:450-455.
6. Ernst J.D. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012, 12:581-591.
7. Hunter R.L. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb) 2011, 91:497-509.
8. Chan J., Flynn J. The immunological aspects of latency in tuberculosis. Clin Immunol 2004, 110:2-12.
9. Gomez J.E., McKinney J.D. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004, 84:29-44.
10. Modlin R.L., Bloom B.R. TB or not TB: that is no longer the question. Sci Transl Med 2013, 5:213sr216.
11. Sperber S.J., Gornish N. Reactivation of tuberculosis during therapy with corticosteroids. Clin Infect Dis 1992, 15:1073-1074.
12. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
13. Selwyn P.A., Hartel D., Lewis V.A., Schoenbaum E.E., Vermund S.H., Klein R.S., et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320:545-550.
14. Dye C., Glaziou P., Floyd K., Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health 2013, 34:271-286.
15. Flynn J.L., Chan J. What's good for the host is good for the bug. Trends Microbiol 2005, 13:98-102.
16. Centers for Disease Control and Prevention Impact of vaccines universally recommended for children--United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999, 48:243-248.
17. Koff W.C., Burton D.R., Johnson P.R., Walker B.D., King C.R., Nabel G.J., et al. Accelerating next-generation vaccine development for global disease prevention. Science 2013, 340:1232910.
18. Andersen P., Kaufmann S.H. Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med 2014, 4.
19. McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 2011, 366:2782-2789.
20. Orme I.M. Vaccine development for tuberculosis: current progress. Drugs 2013, 73:1015-1024.
21. Weiner J., Kaufmann S.H. Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med 2014, 275:467-480.
22. Bloom B.R., Fine P.E.M. The BCG experience: implications for future vaccines against tuberculosis. Tuberculosis: pathogenesis, protection, and control 1994, 531-557. American Society for Microbiology, Washington, DC. B.R. Bloom (Ed.).
23. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698-702.
24. Mangtani P., Abubakar I., Ariti C., Beynon R., Pimpin L., Fine P.E., et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014, 58:470-480.
25. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.
26. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346:1339-1345.
27. D'Argenio D.A., Wilson C.B. A decade of vaccines: integrating immunology and vaccinology for rational vaccine design. Immunity 2010, 33:437-440.
28. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011, 12:509-517.
29. Kumararatne D.S. Tuberculosis and immunodeficiency - of mice and men. Clin Exp Immunol 1997, 107:11-14.
30. Glatman-Freedman A., Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 1998, 11:514-532.
31. Collins F.M. Cellular antimicrobial immunity. CRC Crit Rev Microbiol 1978, 7:27-91.
32. Mackaness G.B. Cellular resistance to infection. J Exp Med 1962, 116:381-406.
33. Kaufmann S.H. Elie Metchnikoff's and Paul Ehrlich's impact on infection biology. Microbes Infect/Institut Pasteur 2008, 10:1417-1419.
34. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406:793-798.
35. Casadevall A. Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle. Infect Immun 2003, 71:4225-4228.
36. Casadevall A., Pirofski L.A. A new synthesis for antibody-mediated immunity. Nat Immunol 2012, 13:21-28.
37. Culkin S.J., Rhinehart-Jones T., Elkins K.L. A novel role for B cells in early protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J Immunol 1997, 158:3277-3284.
38. Langhorne J., Cross C., Seixas E., Li C., von der Weid T. A role for B cells in the development of T cell helper function in a malaria infection in mice. Proc Natl Acad Sci U S A 1998, 95:1730-1734.
39. Li J.S., Winslow G.M. Survival, replication, and antibody susceptibility of Ehrlichia chaffeensis outside of host cells. Infect Immun 2003, 71:4229-4237.
40. Mastroeni P., Simmons C., Fowler R., Hormaeche C.E., Dougan G. Igh-6(-/-) (B-cell-deficient) mice fail to mount solid acquired resistance to oral challenge with virulent Salmonella enterica serovar typhimurium and show impaired Th1 T-cell responses to Salmonella antigens. Infect Immun 2000, 68:46-53.
41. Su H., Feilzer K., Caldwell H.D., Morrison R.P. Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Infect Immun 1997, 65:1993-1999.
42. Woelbing F., Kostka S.L., Moelle K., Belkaid Y., Sunderkoetter C., Verbeek S., et al. Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med 2006, 203:177-188.
43. Yang X., Brunham R.C. Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. J Immunol 1998, 161:1439-1446.
44. Bermejo D.A., Jackson S.W., Gorosito-Serran M., Acosta-Rodriguez E.V., Amezcua-Vesely M.C., Sather B.D., et al. Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells. Nat Immunol 2013, 14:514-522.
45. Casadevall A., Pirofski L. Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Curr Mol Med 2005, 5:421-433.
46. Gibson-Corley K.N., Boggiatto P.M., Bockenstedt M.M., Petersen C.A., Waldschmidt T.J., Jones D.E. Promotion of a functional B cell germinal center response after Leishmania species co-infection is associated with lesion resolution. Am J Pathol 2012, 180:2009-2017.
47. Nanton M.R., Way S.S., Shlomchik M.J., McSorley S.J. Cutting edge: B cells are essential for protective immunity against Salmonella independent of antibody secretion. J Immunol 2012, 189:5503-5507.
48. Rodriguez-Pinto D., Saravia N.G., McMahon-Pratt D. CD4 T cell activation by B cells in human Leishmania (Viannia) infection. BMC Infect Dis 2014, 14:108.
49. Szymczak W.A., Davis M.J., Lundy S.K., Dufaud C., Olszewski M., Pirofski L.A. X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans infection. MBio 2013, 4.
50. Zhang G., Peng Y., Schoenlaub L., Elliott A., Mitchell W., Zhang Y. Formalin-inactivated Coxiella burnetii phase I vaccine-induced protection depends on B cells to produce protective IgM and IgG. Infect Immun 2013, 81:2112-2122.
51. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344:1263-1269.
52. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 2003, 47:833-836.
53. Hoff D.R., Ryan G.J., Driver E.R., Ssemakulu C.C., De Groote M.A., Basaraba R.J., et al. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS ONE 2011, 6:e17550.
54. Fujinami R.S., Oldstone M.B. Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature 1979, 279:529-530.
55. Griffin D.E., Metcalf T. Clearance of virus infection from the CNS. Curr Opin Virol 2011, 1:216-221.
56. Metcalf T.U., Griffin D.E. Alphavirus-induced encephalomyelitis: antibody-secreting cells and viral clearance from the nervous system. J Virol 2011, 85:11490-11501.
57. Yanase K., Smith R.M., Cizman B., Foster M.H., Peachey L.D., Jarett L., et al. A subgroup of murine monoclonal anti-deoxyribonucleic acid antibodies traverse the cytoplasm and enter the nucleus in a time-and temperature-dependent manner. Lab Investig 1994, 71:52-60.
58. Mazanec M.B., Coudret C.L., Fletcher D.R. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995, 69:1339-1343.
59. Mazanec M.B., Kaetzel C.S., Lamm M.E., Fletcher D., Nedrud J.G. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A 1992, 89:6901-6905.
60. Lund F.E., Randall T.D. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010, 10:236-247.
61. Maglione P.J., Chan J. How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol 2009, 39:676-686.
62. Igietseme J.U., Eko F.O., He Q., Black C.M. Antibody regulation of T cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines 2004, 3:23-34.
63. Rawool D.B., Bitsaktsis C., Li Y., Gosselin D.R., Lin Y., Kurkure N.V., et al. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 2008, 180:5548-5557.
64. Elkins K.L., Bosio C.M., Rhinehart-Jones T.R. Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun 1999, 67:6002-6007.
65. Esser M.T., Marchese R.D., Kierstead L.S., Tussey L.G., Wang F., Chirmule N., et al. Memory T cells and vaccines. Vaccine 2003, 21:419-430.
66. Linton P.J., Harbertson J., Bradley L.M. A critical role for B cells in the development of memory CD4 cells. J Immunol 2000, 165:5558-5565.
67. Lund F.E., Hollifield M., Schuer K., Lines J.L., Randall T.D., Garvy B.A. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006, 176:6147-6154.
68. Schultze J.L., Michalak S., Lowne J., Wong A., Gilleece M.H., Gribben J.G., et al. Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses. J Exp Med 1999, 189:1-12.
69. Shen H., Whitmire J.K., Fan X., Shedlock D.J., Kaech S.M., Ahmed R. A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes. J Immunol 2003, 170:1443-1451.
70. Stephens R., Langhorne J. Priming of CD4+ T cells and development of CD4+ T cell memory; lessons for malaria. Parasite Immunol 2006, 28:25-30.
71. Whitmire J.K., Asano M.S., Kaech S.M., Sarkar S., Hannum L.G., Shlomchik M.J., et al. Requirement of B cells for generating CD4+ T cell memory. J Immunol 2009, 182:1868-1876.
72. Wojciechowski W., Harris D.P., Sprague F., Mousseau B., Makris M., Kusser K., et al. Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus. Immunity 2009, 30:421-433.
73. Ise W., Inoue T., McLachlan J.B., Kometani K., Kubo M., Okada T., et al. Memory B cells contribute to rapid Bcl6 expression by memory follicular helper T cells. Proc Natl Acad Sci U S A 2014, 111:11792-11797.
74. Sallusto F., Lanzavecchia A., Araki K., Ahmed R. From vaccines to memory and back. Immunity 2010, 33:451-463.
75. Vinuesa C.G., Tangye S.G., Moser B., Mackay C.R. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005, 5:853-865.
76. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011, 29:621-663.
77. Victora G.D., Nussenzweig M.C. Germinal centers. Annu Rev Immunol 2012, 30:429-457.
78. Cubas R.A., Mudd J.C., Savoye A.L., Perreau M., van Grevenynghe J., Metcalf T., et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 2013, 19:494-499.
79. Locci M., Havenar-Daughton C., Landais E., Wu J., Kroenke M.A., Arlehamn C.L., et al. Human circulating PD-1+ CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013, 39:758-769.
80. Vinuesa C.G. HIV and T follicular helper cells: a dangerous relationship. J Clin Invest 2012, 122:3059-3062.
81. Gray D., Gray M., Barr T. Innate responses of B cells. Eur J Immunol 2007, 37:3304-3310.
82. Kitamura D., Roes J., Kuhn R., Rajewsky K.A. B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991, 350:423-426.
83. Britton S., Mitchison N.A., Rajewsky K. The carrier effect in the secondary response to hapten-protein conjugates. IV. Uptake of antigen in vitro and failure to obtain cooperative induction in vitro. Eur J Immunol 1971, 1:65-68.
84. Mitchison N.A. T-cell-B-cell cooperation. Nat Rev Immunol 2004, 4:308-312.
85. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985, 314:537-539.
86. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 1990, 8:773-793.
87. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
88. Vascotto F., Le Roux D., Lankar D., Faure-Andre G., Vargas P., Guermonprez P., et al. Antigen presentation by B lymphocytes: how receptor signaling directs membrane trafficking. Curr Opin Immunol 2007, 19:93-98.
89. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
90. Weber M.S., Prod'homme T., Patarroyo J.C., Molnarfi N., Karnezis T., Lehmann-Horn K., et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010, 68:369-383.
91. Liu Y., Wu Y., Ramarathinam L., Guo Y., Huszar D., Trounstine M., et al. Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell response. Int Immunol 1995, 7:1353-1362.
92. Kurt-Jones E.A., Liano D., HayGlass K.A., Benacerraf B., Sy M.S., Abbas A.K. The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice. J Immunol 1988, 140:3773-3778.
93. Rodriguez-Pinto D., Moreno J. B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner. Eur J Immunol 2005, 35:1097-1105.
94. Hale J.S., Youngblood B., Latner D.R., Mohammed A.U., Ye L., Akondy R.S., et al. Distinct memory CD4+ T cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after acute viral infection. Immunity 2013, 38:805-817.
95. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005, 238:67-75.
96. Catron D.M., Itano A.A., Pape K.A., Mueller D.L., Jenkins M.K. Visualizing the first 50 hr of the primary immune response to a soluble antigen. Immunity 2004, 21:341-347.
97. Pape K.A., Catron D.M., Itano A.A., Jenkins M.K. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 2007, 26:491-502.
98. Hackett C.J., Rotrosen D., Auchincloss H., Fauci A.S. Immunology research: challenges and opportunities in a time of budgetary constraint. Nat Immunol 2007, 8:114-117.
99. Pepper M., Jenkins M.K. Origins of CD4(+) effector and central memory T cells. Nat Immunol 2011, 12:467-471.
100. Schultze J.L., Grabbe S., von Bergwelt-Baildon M.S. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 2004, 25:659-664.
101. Andersen C.S., Dietrich J., Agger E.M., Lycke N.Y., Lovgren K., Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun 2007, 75:408-416.
102. Helgeby A., Robson N.C., Donachie A.M., Beackock-Sharp H., Lovgren K., Schon K., et al. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells. J Immunol 2006, 176:3697-3706.
103. Hon H., Oran A., Brocker T., Jacob J. B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol 2005, 174:5233-5242.
104. McClellan K.B., Gangappa S., Speck S.H., Virgin H.Wt. Antibody-independent control of gamma-herpesvirus latency via B cell induction of anti-viral T cell responses. PLoS Pathog 2006, 2:e58.
105. Dhodapkar K.M., Kaufman J.L., Ehlers M., Banerjee D.K., Bonvini E., Koenig S., et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A 2005, 102:2910-2915.
106. Kalergis A.M., Ravetch J.V. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002, 195:1653-1659.
107. Mauri C., Gray D., Mushtaq N., Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003, 197:489-501.
108. Mizoguchi A., Ogawa A., Takedatsu H., Sugimoto K., Shimomura Y., Shirane K., et al. Dependence of intestinal granuloma formation on unique myeloid DC-like cells. J Clin Invest 2007, 117:605-615.
109. Rafiq K., Bergtold A., Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002, 110:71-79.
110. Sugimoto K., Ogawa A., Shimomura Y., Nagahama K., Mizoguchi A., Bhan A.K. Inducible IL-12-producing B cells regulate Th2-mediated intestinal inflammation. Gastroenterology 2007, 133:124-136.
111. Liu Y., Janeway C.A. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci U S A 1992, 89:3845-3849.
112. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
113. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010, 28:445-489.
114. Mosmann T. Complexity or coherence? Cytokine secretion by B cells. Nat Immunol 2000, 465-466.
115. Harris D.P., Haynes L., Sayles P.C., Duso D.K., Eaton S.M., Lepak N.M., et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000, 1:475-482.
116. Lund F.E. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008, 20:332-338.
117. Lund F.E., Garvy B.A., Randall T.D., Harris D.P. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005, 8:25-54.
118. Mauri C., Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012, 30:221-241.
119. Candando K.M., Lykken J.M., Tedder T.F. B10 cell regulation of health and disease. Immunol Rev 2014, 259:259-272.
120. Harris D.P., Goodrich S., Gerth A.J., Peng S.L., Lund F.E. Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol 2005, 174:6781-6790.
121. Wagner M., Poeck H., Jahrsdoerfer B., Rothenfusser S., Prell D., Bohle B., et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 2004, 172:954-963.
122. Johansson-Lindbom B., Ingvarsson S., Borrebaeck C.A. Germinal centers regulate human Th2 development. J Immunol 2003, 171:1657-1666.
123. Leon B., Ballesteros-Tato A., Browning J.L., Dunn R., Randall T.D., Lund F.E. Regulation of T(H)2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells. Nat Immunol 2012, 13:681-690.
124. Opata M.M., Ye Z., Hollifield M., Garvy B.A. B cell production of tumor necrosis factor in response to Pneumocystis murina infection in mice. Infect Immun 2013, 81:4252-4260.
125. Shen P., Roch T., Lampropoulou V., O'Connor R.A., Stervbo U., Hilgenberg E., et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014, 507:366-370.
126. Yang L., Yamamoto K., Nishiumi S., Nakamura M., Matsui H., Takahashi S., et al. Interferon-gamma-producing B cells induce the formation of gastric lymphoid follicles after Helicobacter suis infection. Mucosal Immunol 2014.
127. Slight S.R., Rangel-Moreno J., Gopal R., Lin Y., Fallert Junecko B.A., Mehra S., et al. CXCR5(+) T helper cells mediate protective immunity against tuberculosis. J Clin Invest 2013, 123:712-726.
128. Tsai M.C., Chakravarty S., Zhu G., Xu J., Tanaka K., Koch C., et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 2006, 8:218-232.
129. Ulrichs T., Kosmiadi G.A., Jorg S., Pradl L., Titukhina M., Mishenko V., et al. Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. J Infect Dis 2005, 192:89-97.
130. Ulrichs T., Kosmiadi G.A., Trusov V., Jorg S., Pradl L., Titukhina M., et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004, 204:217-228.
131. DiLillo D.J., Matsushita T., Tedder T.F. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010, 1183:38-57.
132. Mizoguchi A., Bhan A.K. A case for regulatory B cells. J Immunol 2006, 176:705-710.
133. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16:219-230.
134. Neves P., Lampropoulou V., Calderon-Gomez E., Roch T., Stervbo U., Shen P., et al. Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during Salmonella typhimurium infection. Immunity 2010, 33:777-790.
135. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47.
136. Amigorena S., Bonnerot C. Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin Immunol 1999, 11:385-390.
137. Nimmerjahn F., Ravetch J.V. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007, 19:239-245.
138. Nimmerjahn F., Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 2006, 24:19-28.
139. Ravetch J.V., Bolland S. IgG Fc receptors. Annu Rev Immunol 2001, 19:275-290.
140. Desai D.D., Harbers S.O., Flores M., Colonna L., Downie M.P., Bergtold A., et al. Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J Immunol 2007, 178:6217-6226.
141. Bandukwala H.S., Clay B.S., Tong J., Mody P.D., Cannon J.L., Shilling R.A., et al. Signaling through Fc{gamma}RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation. J Exp Med 2007, 204:1875-1889.
142. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
143. Shi J., McIntosh R.S., Pleass R.J. Antibody- and Fc-receptor-based therapeutics for malaria. Clin Sci (Lond) 2006, 110:11-19.
144. Park-Min K.H., Serbina N.V., Yang W., Ma X., Krystal G., Neel B.G., et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007, 26:67-78.
145. Moore T., Ekworomadu C.O., Eko F.O., MacMillan L., Ramey K., Ananaba G.A., et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis 2003, 188:617-624.
146. Huber V.C., Lynch J.M., Bucher D.J., Le J., Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001, 166:7381-7388.
147. Kima P.E., Constant S.L., Hannum L., Colmenares M., Lee K.S., Haberman A.M., et al. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J Exp Med 2000, 191:1063-1068.
148. Menager N., Foster G., Ugrinovic S., Uppington H., Verbeek S., Mastroeni P. Fcgamma receptors are crucial for the expression of acquired resistance to virulent Salmonella enterica serovar Typhimurium in vivo but are not required for the induction of humoral or T-cell-mediated immunity. Immunology 2007, 120:424-432.
149. Uppington H., Menager N., Boross P., Wood J., Sheppard M., Verbeek S., et al. Effect of immune serum and role of individual Fcgamma receptors on the intracellular distribution and survival of Salmonella enterica serovar Typhimurium in murine macrophages. Immunology 2006, 119:147-158.
150. Yoneto T., Waki S., Takai T., Tagawa Y., Iwakura Y., Mizuguchi J., et al. A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection. J Immunol 2001, 166:6236-6241.
151. Yuan R., Clynes R., Oh J., Ravetch J.V., Scharff M.D. Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses. J Exp Med 1998, 187:641-648.
152. Maglione P.J., Xu J., Casadevall A., Chan J. Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol 2008, 180:3329-3338.
153. Klimstra W.B., Williams J.C., Ryman K.D., Heidner H.W. Targeting Sindbis virus-based vectors to Fc receptor-positive cell types. Virology 2005, 338:9-21.
154. Tongren J.E., Corran P.H., Jarra W., Langhorne J., Riley E.M. Epitope-specific regulation of immunoglobulin class switching in mice immunized with malarial merozoite surface proteins. Infect Immun 2005, 73:8119-8129.
155. Achkar J.M., Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 2013, 13:250-262.
156. Kozakiewicz L., Phuah J., Flynn J., Chan J. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Adv Exp Med Biol 2013, 783:225-250.
157. Glatman-Freedman A. The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy. Tuberculosis (Edinb) 2006, 86:191-197.
158. de L., Costello A.M., Kumar A., Narayan V., Akbar M.S., Ahmed S., et al. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis. Trans R Soc Trop Med Hyg 1992, 86:686-692.
159. Torrado E., Fountain J.J., Robinson R.T., Martino C.A., Pearl J.E., Rangel-Moreno J., et al. Differential and site specific impact of B cells in the protective immune response to Mycobacterium tuberculosis in the mouse. PLoS ONE 2013, 8:e61681.
160. Kozakiewicz L., Chen Y., Xu J., Wang Y., Dunussi-Joannopoulos K., Ou Q., et al. B cells regulate neutrophilia during Mycobacterium tuberculosis Infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog 2013, 9:e1003472.
161. Hamasur B., Haile M., Pawlowski A., Schroder U., Kallenius G., Svenson S.B. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol 2004, 138:30-38.
162. Pethe K., Alonso S., Biet F., Delogu G., Brennan M.J., Locht C., et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001, 412:190-194.
163. Reljic R., Clark S.O., Williams A., Falero-Diaz G., Singh M., Challacombe S., et al. Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection. Clin Exp Immunol 2006, 143:467-473.
164. Teitelbaum R., Glatman-Freedman A., Chen B., Robbins J.B., Unanue E., Casadevall A., et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A 1998, 95:15688-15693.
165. Williams A., Reljic R., Naylor I., Clark S.O., Falero-Diaz G., Singh M., et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 2004, 111:328-333.
166. Chambers M.A., Gavier-Widén D., Glyn Hewinson R. Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge. FEMS Immunol Med Microbiol 2004, 41:93-100.
167. Guirado E., Amat I., Gil O., Diaz J., Arcos V., Caceres N., et al. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect 2006, 8:1252-1259.
168. Roy E., Stavropoulos E., Brennan J., Coade S., Grigorieva E., Walker B., et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 2005, 73:6101-6109.
169. de Valliere S., Abate G., Blazevic A., Heuertz R.M., Hoft D.F. Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies. Infect Immun 2005, 73:6711-6720.
170. Hamasur B., Haile M., Pawlowski A., Schroder U., Williams A., Hatch G., et al. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine 2003, 21:4081-4093.
171. Ehrenstein M.R., Notley C.A. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 2010, 10:778-786.
172. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 2011, 11:34-46.
173. Cerutti A., Cols M., Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 2013, 13:118-132.
174. Hardy R.R., Hayakawa K. CD5 B cells, a fetal B cell lineage. Adv Immunol 1994, 55:297-339.
175. Kantor A.B., Herzenberg L.A. Origin of murine B cell lineages. Annu Rev Immunol 1993, 11:501-538.
176. Cooper N.R. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 1985, 37:151-216.
177. Racine R., Winslow G.M. IgM in microbial infections: taken for granted. Immunol Lett 2009, 125:79-85.
178. Salinas-Carmona M.C., Pérez-Rivera I. Humoral immunity through immunoglobulin M protects mice from an experimental actinomycetoma infection by Nocardia brasiliensis. Infect Immun 2004, 72:5597-5604.
179. Salinas-Carmona M.C., Torres-López E. Role of passive humoral immunity in experimental mycetoma by Nocardia brasiliensis. Ann N Y Acad Sci 1996, 797:263-265.
180. Cole L.E., Yang Y., Elkins K.L., Fernandez E.T., Qureshi N., Shlomchik M.J., et al. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A 2009, 106:4343-4348.
181. Dreisbach V.C., Cowley S., Elkins K.L. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infect Immun 2000, 68:1988-1996.
182. Fulop M., Mastroeni P., Green M., Titball R.W. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 2001, 19:4465-4472.
183. Savitt A.G., Mena-Taboada P., Monsalve G., Benach J.L. Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clin Vaccine Immunol 2009, 16:414-422.
184. Racine R., Chatterjee M., Winslow G.M. CD11c expression identifies a population of extrafollicular antigen-specific splenic plasmablasts responsible for CD4 T-independent antibody responses during intracellular bacterial infection. J Immunol 2008, 181:1375-1385.
185. Racine R., McLaughlin M., Jones D.D., Wittmer S.T., MacNamara K.C., Woodland D.L., et al. IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection. J Immunol 2011, 186:1011-1021.
186. Alugupalli K.R., Leong J.M., Woodland R.T., Muramatsu M., Honjo T., Gerstein R.M. B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity 2004, 21:379-390.
187. Haas K.M., Poe J.C., Steeber D.A., Tedder T.F. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 2005, 23:7-18.
188. Baumgarth N., Herman O.C., Jager G.C., Brown L.E., Herzenberg L.A., Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med 2000, 192:271-280.
189. Rapaka R.R., Ricks D.M., Alcorn J.F., Chen K., Khader S.A., Zheng M., et al. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J Exp Med 2010, 207:2907-2919.
190. Boes M., Esau C., Fischer M.B., Schmidt T., Carroll M., Chen J. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J Immunol 1998, 160:4776-4787.
191. Ehrenstein M.R., O'Keefe T.L., Davies S.L., Neuberger M.S. Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response. Proc Natl Acad Sci U S A 1998, 95:10089-10093.
192. Applequist S.E., Dahlström J., Jiang N., Molina H., Heyman B. Antibody production in mice deficient for complement receptors 1 and 2 can be induced by IgG/Ag and IgE/Ag, but not IgM/Ag complexes. J Immunol 2000, 165:2398-2403.
193. Heyman B., Pilström L., Shulman M.J. Complement activation is required for IgM-mediated enhancement of the antibody response. J Exp Med 1988, 167:1999-2004.
194. Rutemark C., Bergman A., Getahun A., Hallgren J., Henningsson F., Heyman B. Complement receptors 1 and 2 in murine antibody responses to IgM-complexed and uncomplexed sheep erythrocytes. PLoS ONE 2012, 7:e41968.
195. Shima H., Takatsu H., Fukuda S., Ohmae M., Hase K., Kubagawa H., et al. Identification of TOSO/FAIM3 as an Fc receptor for IgM. Int Immunol 2010, 22:149-156.
196. Choi S.-C., Wang H., Tian L., Murakami Y., Shin D-M., Borrego F., et al. Mouse IgM Fc receptor, FCMR, promotes B cell development and modulates antigen-driven immune responses. J Immunol 2013, 190:987-996.
197. Honjo K., Kubagawa Y., Jones D.M., Dizon B., Zhu Z., Ohno H., et al. Altered Ig levels and antibody responses in mice deficient for the Fc receptor for IgM (Fc(R). Proc Natl Acad Sci U S A 2012, 109:15882-15887.
198. Ouchida R., Mori H., Hase K., Takatsu H., Kurosaki T., Tokuhisa T., et al. Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival, and humoral immune responses. Proc Natl Acad Sci U S A 2012, 109:E2699-E2706.
199. Kubagawa H., Oka S., Kubagawa Y., Torii I., Takayama E., Kang D-W., et al. Identity of the elusive IgM Fc receptor (Fc(R) in humans. J Exp Med 2009, 206:2779-2793.
200. Casadevall A., Pirofski L.A. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 2006, 91:1-44.
201. Aurora A.B., Baluk P., Zhang D., Sidhu S.S., Dolganov G.M., Basbaum C., et al. Immune complex-dependent remodeling of the airway vasculature in response to a chronic bacterial infection. J Immunol 2005, 175:6319-6326.
202. Maglione P.J., Xu J., Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol 2007, 178:7222-7234.
203. Clynes R. Protective mechanisms of IVIG. Curr Opin Immunol 2007, 19:646-651.
204. Bournazos S., Woof J.M., Hart S.P., Dransfield I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol 2009, 157:244-254.
205. Li X., Gibson A., Kimberly R. Human FcR polymorphism and disease. Fc receptor 2014, 275-302. Springer International Publishing. M. Daeron, F. Nimmerjahn (Eds.).
206. Cooke G.S., Aucan C., Walley A.J., Segal S., Greenwood B.M., Kwiatkowski D.P., et al. Association of Fcgamma receptor IIa (CD32) polymorphism with severe malaria in West Africa. Am J Trop Med Hyg 2003, 69:565-568.
207. Forthal D.N., Landucci G., Bream J., Jacobson L.P., Phan T.B., Montoya B. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol 2007, 179:7916-7923.
208. Platonov A.E., Kuijper E.J., Vershinina I.V., Shipulin G.A., Westerdaal N., Fijen C.A., et al. Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals. Clin Exp Immunol 1998, 111:97-101.
209. van der Pol W.L., Huizinga T.W., Vidarsson G., van der Linden M.W., Jansen M.D., Keijsers V., et al. Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001, 184:1548-1555.
210. Yoshie H., Kobayashi T., Tai H., Galicia J.C. The role of genetic polymorphisms in periodontitis. Periodontol 2000 2007, 43:102-132.
211. Biezeveld M., Geissler J., Merkus M., Kuipers I.M., Ottenkamp J., Kuijpers T. The involvement of Fc gamma receptor gene polymorphisms in Kawasaki disease. Clin Exp Immunol 2007, 147:106-111.
212. Dijstelbloem H.M., Scheepers R.H., Oost W.W., Stegeman C.A., van der Pol W.L., Sluiter W.J., et al. Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum 1999, 42:1823-1827.
213. Morgan A.W., Robinson J.I., Barrett J.H., Martin J., Walker A., Babbage S.J., et al. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther 2006, 8:R109.
214. Sadki K., Lamsyah H., Rueda B., Akil E., Sadak A., Martin J., et al. Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population. J Genet Genomics=Yi Chuan Xue Bao 2010, 37:257-264.
215. Jacobsen M., Repsilber D., Gutschmidt A., Neher A., Feldmann K., Mollenkopf H.J., et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) 2007, 85:613-621.
216. Maertzdorf J., Ota M., Repsilber D., Mollenkopf H.J., Weiner J., Hill P.C., et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS ONE 2011, 6:e26938.
217. Maertzdorf J., Repsilber D., Parida S.K., Stanley K., Roberts T., Black G., et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immunity 2011, 12:15-22.
218. Sutherland J.S., Loxton A.G., Haks M.C., Kassa D., Ambrose L., Lee J.S., et al. Differential gene expression of activating Fcgamma receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect 2014, 20:O230-O238.
219. Cliff J.M., Lee J.S., Constantinou N., Cho J.E., Clark T.G., Ronacher K., et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 2013, 207:18-29.
220. van der Poel C.E., Spaapen R.M., van de Winkel J.G., Leusen J.H. Functional characteristics of the high affinity IgG receptor, FcgammaRI. J Immunol 2011, 186:2699-2704.
221. Junqueira-Kipnis A.P., Kipnis A., Henao Tamayo M., Harton M., Gonzalez Juarrero M., Basaraba R.J., et al. Interleukin-10 production by lung macrophages in CBA xid mutant mice infected with Mycobacterium tuberculosis. Immunology 2005, 115:246-252.
222. Moore K.W., De Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
223. Rutella S., Danese S., Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006, 108:1435-1440.
224. Olson T.S., Bamias G., Naganuma M., Rivera-Nieves J., Burcin T.L., Ross W., et al. Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J Clin Invest 2004, 114:389-398.
225. Redford P.S., Murray P.J., O'Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 2011, 4:261-270.
226. Bosio C.M., Gardner D., Elkins K.L. Infection of B cell-deficient mice with CDC 1551, a clinical isolate of Mycobacterium tuberculosis: delay in dissemination and development of lung pathology. J Immunol 2000, 164:6417-6425.
227. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006, 6:205-217.
228. Pitzalis C., Jones G.W., Bombardieri M., Jones S.A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 2014, 14:447-462.
229. Hunter R.L. On the pathogenesis of post primary tuberculosis: the role of bronchial obstruction in the pathogenesis of cavities. Tuberculosis (Edinb) 2011, 91(Suppl. 1):S6-S10.
230. Casadevall A., Pirofski L.A. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003, 1:17-24.
231. Dheda K., Booth H., Huggett J.F., Johnson M.A., Zumla A., Rook G.A. Lung remodeling in pulmonary tuberculosis. J Infect Dis 2005, 192:1201-1209.
232. Moraes T.J., Zurawska J.H., Downey G.P. Neutrophil granule contents in the pathogenesis of lung injury. Curr Opin Hematol 2006, 13:21-27.
233. Eruslanov E.B., Lyadova I.V., Kondratieva T.K., Majorov K.B., Scheglov I.V., Orlova M.O., et al. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infect Immun 2005, 73:1744-1753.
234. Gonzalez-Juarrero M., Turner O.C., Turner J., Marietta P., Brooks J.V., Orme I.M. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect Immun 2001, 69:1722-1728.
235. Turner J., Frank A.A., Brooks J.V., Gonzalez-Juarrero M., Orme I.M. The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4. Exp Gerontol 2001, 36:537-545.
236. Khader S.A., Rangel-Moreno J., Fountain J.J., Martino C.A., Reiley W.W., Pearl J.E., et al. In a murine tuberculosis model, the absence of homeostatic chemokines delays granuloma formation and protective immunity. J Immunol 2009, 183:8004-8014.
237. Phuah J.Y., Mattila J.T., Lin P.L., Flynn J.L. Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis. Am J Pathol 2012, 181:508-514.
238. Moyron-Quiroz J.E., Rangel-Moreno J., Hartson L., Kusser K., Tighe M.P., Klonowski K.D., et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 2006, 25:643-654.
239. Moyron-Quiroz J.E., Rangel-Moreno J., Kusser K., Hartson L., Sprague F., Goodrich S., et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004, 10:927-934.
240. Kaufmann S.H. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 2007, 5:491-504.
241. Chow S.K., Smith C., MacCarthy T., Pohl M.A., Bergman A., Casadevall A. Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies. Cell Host Microbe 2013, 13:417-428.